Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...

Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...